ScripFrontline Indian firms appear keen to accelerate product in-licensing deals with foreign companies and these efforts have now evolved from a “supplementary tactic” to a cornerstone of their strategy,
ScripActithera has raised $75.5m in a series A financing to develop radioligand therapies (RLTs) that use a covalent drug design to prolong their effects on cancer cells. The early-stage company’s lead can
ScripIn a momentous moment for the fight against malaria, Novartis has gained approval for a drug to treat the potentially deadly mosquito-borne disease in babies and very young children. Novartis, which b
ScripThe recent removal of the Risk Evaluation and Mitigation Strategies (REMS) requirement for approved cellular CAR-T therapies for cancer was lauded as an expansion of the market from the two-in-10 el